Abstract
Screening and treatment of prostate cancer remain controversial, particularly for elderly men. Since the previous United States Preventive Services Task Force recommendation in 2008 against prostate-specific antigen (PSA) screening after age 75 years, there has not been a substantial reduction in the frequency of PSA testing in this age group. A substantial proportion of elderly men are overdiagnosed and overtreated. On the other hand, men aged >75 years have more aggressive disease. Although screening has questionable benefit for elderly men with significant comorbidities, healthy men >75 years may benefit from definitive therapy. This review discusses prostate cancer screening and management decisions for elderly men, including the use of nomograms and predictive tools for life expectancy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
